$23.07 Million in Sales Expected for Theravance Biopharma Inc (NASDAQ:TBPH) This Quarter

Analysts expect that Theravance Biopharma Inc (NASDAQ:TBPH) will announce $23.07 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Theravance Biopharma’s earnings, with estimates ranging from $16.00 million to $30.00 million. Theravance Biopharma posted sales of $26.15 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 11.8%. The business is expected to announce its next quarterly earnings results on Wednesday, July 29th.

On average, analysts expect that Theravance Biopharma will report full-year sales of $110.15 million for the current financial year, with estimates ranging from $101.91 million to $125.00 million. For the next financial year, analysts anticipate that the company will post sales of $151.25 million, with estimates ranging from $100.38 million to $207.59 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Theravance Biopharma.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.40) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.33). The business had revenue of $19.86 million during the quarter, compared to analysts’ expectations of $18.02 million.

A number of brokerages have commented on TBPH. Zacks Investment Research downgraded Theravance Biopharma from a “strong-buy” rating to a “hold” rating and set a $34.00 target price on the stock. in a research note on Tuesday, May 12th. Morgan Stanley began coverage on Theravance Biopharma in a research note on Monday, June 15th. They issued an “equal weight” rating and a $30.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $32.00 target price on shares of Theravance Biopharma in a research note on Thursday, May 7th. BidaskClub cut Theravance Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, June 20th. Finally, Cowen initiated coverage on Theravance Biopharma in a research report on Wednesday, May 13th. They issued an “outperform” rating and a $42.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $35.00.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Engineers Gate Manager LP lifted its position in shares of Theravance Biopharma by 13.7% during the 1st quarter. Engineers Gate Manager LP now owns 40,621 shares of the biopharmaceutical company’s stock worth $939,000 after purchasing an additional 4,886 shares during the last quarter. BlackRock Inc. lifted its position in shares of Theravance Biopharma by 129.3% during the 1st quarter. BlackRock Inc. now owns 8,780,790 shares of the biopharmaceutical company’s stock worth $202,923,000 after purchasing an additional 4,951,711 shares during the last quarter. State Street Corp lifted its position in shares of Theravance Biopharma by 10.0% during the 1st quarter. State Street Corp now owns 1,055,268 shares of the biopharmaceutical company’s stock worth $24,387,000 after purchasing an additional 95,704 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Theravance Biopharma by 17.6% during the 1st quarter. Geode Capital Management LLC now owns 719,072 shares of the biopharmaceutical company’s stock worth $16,617,000 after purchasing an additional 107,724 shares during the last quarter. Finally, Arizona State Retirement System acquired a new position in shares of Theravance Biopharma during the 1st quarter worth about $231,000. 88.47% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ TBPH opened at $19.94 on Friday. The business’s 50-day moving average price is $24.22 and its two-hundred day moving average price is $25.28. Theravance Biopharma has a one year low of $15.72 and a one year high of $31.54. The company has a market capitalization of $1.26 billion, a P/E ratio of -4.59 and a beta of 1.43.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

Featured Story: Consumer Price Index (CPI)

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.